Stem Cell Therapy

Stem cell therapy is a branch of regenerative medicine focused on restoring function in damaged tissues and organs by supporting the body’s natural repair mechanisms.

Because of their ability to influence surrounding cells and biological processes, stem cells are among the most widely studied tools in modern medicine. At the same time, stem cell therapy remains an evolving area of medicine and is applied within controlled clinical environments.

The ANOVA Institute of Regenerative Medicine (ANOVA IRM) has operated within a regulated German medical framework since 2018, offering stem cell-based therapies applied within a medically guided framework. 

In clinical settings, stem cell therapy refers to a range of regenerative approaches that use stem cells or stem cell-derived products to support tissue repair and functional recovery.

These therapies often involve the use of stem cells sourced from the patient’s own body, such as bone marrow or adipose (fat) tissue, and are applied differently depending on the condition being addressed and the therapeutic objective.

Because most applications are still considered experimental, treatment is typically delivered within regulated medical settings where it is guided by established safety and quality protocols.

At ANOVA IRM, therapy is based on autologous treatment concepts and performed within a regulated German medical framework. Stem cell products are manufactured and controlled according to established standards such as GMP, GFP, and the European Pharmacopoeia.

What You Need to Know About Stem Cells →

Stem cell therapy works by influencing healing, inflammation, and regenerative activity within the body.

Rather than acting through a single mechanism, these effects are driven not only by the cells themselves, but also by the signalling molecules they release. These molecules play a key role in how cells communicate, respond to injury, and regulate inflammation.

In this context, stem cells are not simply replacing damaged tissue. Instead, they help create conditions that support the body’s own repair processes, including reducing excessive inflammation and promoting tissue recovery.

This understanding is central to how treatment is approached at ANOVA IRM. Because these effects vary by condition and treatment method, each patient is evaluated individually, with appropriate methods, including cell-based and signalling-based therapies, selected based on clinical findings. If stem cell therapy is not suitable, alternative options may be recommended.

ANOVA IRM offers a range of stem cell-based treatment options selected based on the patient’s condition and treatment goals. Treatment selection is based on whether localized regenerative support, broader systemic application, or signalling-based therapy is most appropriate.

Bone Marrow Concentrate (BMC)

Bone Marrow Concentrate (BMC) is an autologous treatment derived from the patient’s own bone marrow. It contains a concentrated mix of bone marrow cells and other regenerative components that help support localized healing and tissue repair.

At ANOVA, BMC is used in treatment strategies where a direct regenerative approach is appropriate, particularly for selected orthopaedic and musculoskeletal conditions. The collected bone marrow is concentrated and re-applied without cell cultivation or multiplication, making it a distinct option within ANOVA’s broader treatment model.

Explore Bone Marrow Concentrate (BMC) →

Stem Cell Secretome / Exosomes Therapy

Stem Cell Secretome Therapy is a cell-free regenerative treatment based on the bioactive signalling molecules released by mesenchymal stem cells. Rather than applying living stem cells directly, this approach is designed to harness the regenerative and immunomodulatory effects of the signalling molecules those cells release.

Secretome Therapy is positioned at ANOVA IRM as a next-generation treatment approach, particularly where repeated, signalling-based application may be more appropriate within a broader treatment plan. Because it is cell-free, it represents a distinct option within ANOVA’s stem cell therapy model.

Explore Stem Cell Secretome / Exosomes Therapy →

Mesenchymal Stem Cells (MSCs)

Mesenchymal stem cells (MSCs) are adult multipotent stem cells known for their regenerative and immunomodulatory properties. They are widely studied because of their ability to influence healing, regulate inflammation, and support tissue repair.

At ANOVA IRM, MSCs are not used as a standalone treatment. Instead, they are present within Bone Marrow Concentrate (BMC) and are also the source of the bioactive signalling molecules used in Stem Cell Secretome Therapy.

Because of their biological role, MSCs are central to how these treatment approaches function, particularly in signalling-based therapies.

Explore Mesenchymal Stem Cells (MSCs) →

Choosing whether to pursue stem cell therapy can feel overwhelming, especially with so much conflicting information available. At ANOVA IRM, treatment is delivered within a controlled, medically guided framework.

What this means for you:

• Treatment is guided by your clinical picture
  Within this framework, treatment decisions are based on diagnosis, clinical findings, and how therapy can be applied in practice. 
• Autologous treatment concepts
  All therapies are based on the patient’s own biological material, improving compatibility and reducing risks associated with donor-derived approaches. 
• Therapy is selected based on how the condition is best addressed
  Depending on the condition, treatment may involve a localized regenerative approach, a broader systemic strategy, or a signalling-based therapy such as Stem Cell Secretome. 
• Stem cell products are applied within a controlled medical framework
  All therapies are performed within a regulated German medical setting, with products manufactured and controlled according to standards such as GMP, GFP, and the European Pharmacopoeia. 
• Treatment methods are selected within a defined clinical framework
  ANOVA focuses on a small number of treatment approaches that have been carefully developed, validated, and approved within a regulated medical environment. These methods are based on clinical rationale, safety considerations, and established protocols, and are not changed or expanded rapidly. 
• Stem cell therapy is part of a broader treatment strategy
  It is integrated into a structured medical plan rather than presented as a standalone or universal solution. 

At ANOVA IRM, stem cell therapies are based on autologous treatment approaches, meaning the cells or biological material used in treatment are derived from the patient’s own body.

This approach improves compatibility and reduces risks associated with donor-derived (allogeneic) therapies, including immune reactions, transmission of infectious agents, and variability in product quality.

It also allows for a more controlled and individualized treatment process. By working with patient-specific biological material, therapy can be planned and applied in alignment with the patient’s condition, treatment goals, and overall clinical profile.

Stem cell therapy is primarily explored in conditions involving inflammation, degeneration, or immune system dysfunction.

At ANOVA IRM, treatment is focused on selected condition categories where stem cell-based therapies may be applied within a medically guided, patient-specific treatment strategy.

These categories include:

• Neurodegenerative Conditions
• Autoimmune and Chronic Inflammatory Conditions
• Orthopaedic and Musculoskeletal Conditions
• Chronic and Systemic Conditions

Each category includes a range of specific diagnoses, with treatment approaches adapted based on clinical findings, disease progression, and individual treatment goals.

Explore All Conditions Treated With Stem Cell Therapy →

Not all patients are suitable candidates for stem cell therapy. Eligibility depends on the diagnosis, overall health, and whether treatment is medically appropriate based on the individual case.

At ANOVA IRM, treatment is only considered after a detailed medical review and diagnostic assessment. The goal is to determine whether the expected benefit justifies treatment, and which therapeutic approach is most appropriate based on the patient’s condition, imaging findings, and broader clinical picture.

Learn how candidacy is evaluated in our Diagnostic Work-Up overview →

The safety of stem cell therapy is not defined by the procedure alone. Safety depends on how the treatment is sourced, processed, and applied, and whether it is planned within a medically supervised setting.

Because many stem cell therapies are still considered experimental, careful evaluation is essential. Clear diagnostics, controlled processing, medical oversight, and realistic treatment planning all play a critical role in determining whether therapy is appropriate.

At ANOVA IRM, treatment decisions are based on clinical findings and individual suitability, with a focus on controlled application rather than standardized protocols.

Contraindications

Stem cell therapies are considered experimental in many applications and are applied following medical evaluation to determine suitability in each individual case.

Because ANOVA IRM uses autologous treatment approaches and controlled clinical protocols, the overall risk profile is generally low. However, treatment is not appropriate in all situations, and certain conditions may limit or prevent treatment.

At ANOVA IRM, treatment is not offered in the following situations:

• Active cancer within the last two years
• Not yet of legal age
• Pregnancy or lactation
• Inability to breathe independently (ventilator-dependent)
• Difficulty breathing in a supine position
• Severe dysphagia (difficulty swallowing)
• Certain psychiatric disorders
• Active infectious disease (such as hepatitis, HIV, syphilis, or other infections)

Choosing where to pursue stem cell therapy is an important decision. At ANOVA IRM, treatment is guided by a structured, medically supervised approach designed to ensure safety, precision, and individualized care.

Patients choose ANOVA IRM for:

• Individualized treatment planning based on diagnosis and clinical findings
• Use of autologous stem cell approaches to support compatibility and safety
• Controlled processing and quality standards within a regulated German medical framework
• Access to advanced diagnostics to guide treatment decisions
• Coordinated care for international patients traveling to Germany

Request a consultation to find out whether stem cell therapy may be appropriate for your condition.